Nurix Therapeutics (NRIX) Research & Development (2019 - 2026)

Nurix Therapeutics (NRIX) has 8 years of Research & Development data on file, last reported at $87.7 million in Q2 2026.

• On a quarterly basis, Research & Development rose 12.24% year-over-year to $87.7 million in Q2 2026; TTM through May 2026 was $340.9 million, a 26.06% increase from a year earlier, with the FY2025 full-year figure at $316.9 million, up 42.99% from the prior year.
• Research & Development for Q2 2026 stood at $87.7 million, up from $84.1 million in the prior quarter.
• Over the last five years, Research & Development for NRIX reached as high as $87.7 million in Q2 2026 and fell as low as $43.1 million in Q1 2022.
• Historically, Research & Development has averaged $60.2 million across 5 years, with a median of $49.9 million in 2023.
• Across the five-year window, Research & Development jumped 87.53% in 2022 and decreased 3.64% in 2023, its largest moves.
• Year by year, Research & Development stood at $46.1 million in 2022, then gained by 7.82% to $49.7 million in 2023, then soared by 35.22% to $67.2 million in 2024, then increased by 23.5% to $83.0 million in 2025, then grew by 5.58% to $87.7 million in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $87.7 million in Q2 2026, $84.1 million in Q1 2026, and $83.0 million in Q4 2025.